@inproceedings{inproceedings, title  = {{A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs}},

 url = {{}},

 year = {{2013}},

 month = {{5}},

 author = {{Wolin EM and Jarzab B and Eriksson B and Walter T and Toumpanakis C and Morse M and Tomassetti P and Weber M and Fogelman DR and Ramage J and Poon D et al}},

 volume = {{31}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{15}},

 note = {{Accessed on 2024/12/22}}}